Physician profile
Emma Simpson
NPI 1396122412
$1,357.63
in general payments reported to CMS, 2019-2025
16 companies · $204 in 2025
The $204 reported for 2025 was more than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.33 · 2021: $208 · 2022: $561 · 2023: $356 · 2024: $14.29 · 2025: $204.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $575.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $574.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $306.63 | 2022-2025 | Tyvaso |
| Olympus America INC. | $290.78 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $164.52 | 2022-2023 | Tagrisso, Fasenra, Breztri |
| Regeneron Healthcare Solutions, INC. | $100.76 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.18 | 2021-2022 | |
| Exthera Medical Corporation | $73.57 | 2022 | |
| Genzyme Corporation | $61.89 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $43.14 | 2022-2023 | Glassia |
| Actelion Pharmaceuticals US, INC. | $40.06 | 2022-2023 | Uptravi, Opsumit |
| Insmed, INC. | $37.71 | 2022-2023 | Arikayce |
| Grifols USA, LLC | $36.73 | 2022-2023 | Prolastin-C Liquid |
| Getinge USA Sales, LLC | $32.76 | 2021 | |
| Glaxosmithkline, LLC. | $31.52 | 2022-2023 | Nucala |
| Mylan Specialty L.P. | $28.69 | 2019-2023 | Yupelri |
| Amgen INC. | $15.40 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Accord Healthcare, INC. | $14.29 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emma Simpson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.